Home  »  Business   »  Nabriva Therapeutics plc (NASDAQ: NBRV) Has Outsta...

Nabriva Therapeutics plc (NASDAQ: NBRV) Has Outstanding Potential

Nabriva Therapeutics plc (NASDAQ:NBRV) shares, rose in value on Friday, 05/13/22, with the stock price up by 8.03% to the previous day’s close as strong demand from buyers drove the stock to $0.22.

Actively observing the price movement in the last trading, the stock closed the session at $0.21, falling within a range of $0.2037 and $0.235. The value of beta (5-year monthly) was 1.62. Referring to stock’s 52-week performance, its high was $2.32, and the low was $0.20. On the whole, NBRV has fluctuated by -39.11% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


With the market capitalization of Nabriva Therapeutics plc currently standing at about $15.12 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 09, 2022 – Mar 14, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.21, which is expected to increase to -$0.2 for fiscal year -$1.12 and then to about -$0.67 by fiscal year 2022. Data indicates that the EPS growth is expected to be 79.30% in 2022, while the next year’s EPS growth is forecast to be 40.20%.

Analysts have estimated the company’s revenue for the quarter at $9.85 million, with a low estimate of $9.85 million and a high estimate of $9.85 million. According to the average forecast, sales growth in current quarter could jump up 300.40%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $29.48 million, representing an increase of 486.40% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that NBRV’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of NBRV currently trading nearly -25.18% and -40.35% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 27.52, while the 7-day volatility ratio is showing 16.97% which for the 30-day chart, stands at 11.17%. Furthermore, Nabriva Therapeutics plc (NBRV)’s beta value is 1.57, and its average true range (ATR) is 0.03.

A comparison of Nabriva Therapeutics plc (NBRV) with its peers suggests the former has fared considerably weaker in the market. NBRV showed an intraday change of 8.03% in last session, and over the past year, it shrunk by -84.29%%. On the other hand, the price of Omeros Corporation (OMER) has risen 8.47% on the day. The stock, however, is off -82.42% from where it was a year ago. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.

Data on historical trading for Nabriva Therapeutics plc (NASDAQ:NBRV) indicates that the trading volumes over the past 10 days have averaged 0.65 million and over the past 3 months, they’ve averaged 442.59K. According to company’s latest data on outstanding shares, there are 58.79 million shares outstanding.

Nearly 1.10% of Nabriva Therapeutics plc’s shares belong to company insiders and institutional investors own 15.90% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.11 million shares as on Dec 14, 2021, resulting in a short ratio of 1.38. According to the data, the short interest in Nabriva Therapeutics plc (NBRV) stood at 1.97% of shares outstanding as of Dec 14, 2021; the number of short shares registered in Nov 14, 2021 reached 1.17 million. The stock has fallen by -62.48% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NBRV stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts


New Outlook On Pfizer Inc.

Pfizer Inc. (NYSE:PFE) price on Thursday, May 26, rose 1.69% above its previous day’s close as an upside momentum from buyers pushed the stock’s value



Download Free eBook For


100% free. stop anytime no spam